From Name

From Email

To Name

To Email

Message

Icosapent Ethyl Reduces Coronary Revascularization by 11 Months: REDUCE-IT REVASC

from Healio

Icosapent Ethyl Reduces Coronary Revascularization by 11 Months: REDUCE-IT REVASC Healio Icosapent ethyl demonstrated a very early coronary revascularization benefit, according to findings from REDUCE-IT REVASC. The data, presented at the virtual American Society for Preventive Cardiology Congress on CVD Prevention, determined that the benefit in patients assigned icosapent ethyl (Vascepa, Amarin) met statistical significance by 11 months. Some data presented at ASPC were also presented at the virtual Society for Cardiovascular Angiography and Interventions Scientific Sessions in May. READ MORE

more